168 related articles for article (PubMed ID: 12657615)
1. Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.
Rakic JM; Lambert V; Munaut C; Bajou K; Peyrollier K; Alvarez-Gonzalez ML; Carmeliet P; Foidart JM; Noël A
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1732-9. PubMed ID: 12657615
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model.
Das A; Boyd N; Jones TR; Talarico N; McGuire PG
Arch Ophthalmol; 2004 Dec; 122(12):1844-9. PubMed ID: 15596589
[TBL] [Abstract][Full Text] [Related]
3. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.
Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS
Am J Physiol Heart Circ Physiol; 2001 Oct; 281(4):H1784-92. PubMed ID: 11557572
[TBL] [Abstract][Full Text] [Related]
4. The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization.
Cammalleri M; Dal Monte M; Locri F; Lista L; Aronsson M; Kvanta A; Rusciano D; De Rosa M; Pavone V; André H; Bagnoli P
Invest Ophthalmol Vis Sci; 2016 May; 57(6):2600–2611. PubMed ID: 27168367
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.
Lund LR; Green KA; Stoop AA; Ploug M; Almholt K; Lilla J; Nielsen BS; Christensen IJ; Craik CS; Werb Z; Danø K; Rømer J
EMBO J; 2006 Jun; 25(12):2686-97. PubMed ID: 16763560
[TBL] [Abstract][Full Text] [Related]
6. Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice.
Levi M; Moons L; Bouché A; Shapiro SD; Collen D; Carmeliet P
Circulation; 2001 Apr; 103(15):2014-20. PubMed ID: 11306532
[TBL] [Abstract][Full Text] [Related]
7. Mice lacking tPA, uPA, or plasminogen genes showed delayed functional recovery after sciatic nerve crush.
Siconolfi LB; Seeds NW
J Neurosci; 2001 Jun; 21(12):4348-55. PubMed ID: 11404420
[TBL] [Abstract][Full Text] [Related]
8. The urokinase/urokinase receptor system in retinal neovascularization: inhibition by A6 suggests a new therapeutic target.
McGuire PG; Jones TR; Talarico N; Warren E; Das A
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2736-42. PubMed ID: 12766081
[TBL] [Abstract][Full Text] [Related]
9. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator.
Schäfer K; Konstantinides S; Riedel C; Thinnes T; Müller K; Dellas C; Hasenfuss G; Loskutoff DJ
Circulation; 2002 Oct; 106(14):1847-52. PubMed ID: 12356640
[TBL] [Abstract][Full Text] [Related]
10. Receptor-independent role of the urokinase-type plasminogen activator during arteriogenesis.
Deindl E; Ziegelhöffer T; Kanse SM; Fernandez B; Neubauer E; Carmeliet P; Preissner KT; Schaper W
FASEB J; 2003 Jun; 17(9):1174-6. PubMed ID: 12692088
[TBL] [Abstract][Full Text] [Related]
11. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials.
Lambert V; Munaut C; Carmeliet P; Gerard RD; Declerck PJ; Gils A; Claes C; Foidart JM; Noël A; Rakic JM
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2791-7. PubMed ID: 12766088
[TBL] [Abstract][Full Text] [Related]
13. Expression of plasminogen activator and inhibitor, urokinase receptor and inhibin subunits in rhesus monkey testes.
Zhang T; Zhou HM; Liu YX
Mol Hum Reprod; 1997 Mar; 3(3):223-31. PubMed ID: 9237248
[TBL] [Abstract][Full Text] [Related]
14. Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.
Piguet PF; Da Laperrousaz C; Vesin C; Tacchini-Cottier F; Senaldi G; Grau GE
Infect Immun; 2000 Jul; 68(7):3822-9. PubMed ID: 10858190
[TBL] [Abstract][Full Text] [Related]
15. Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice.
Ahn MY; Zhang ZG; Tsang W; Chopp M
Brain Res; 1999 Aug; 837(1-2):169-76. PubMed ID: 10433999
[TBL] [Abstract][Full Text] [Related]
16. The role of the urokinase-type plasminogen activator (uPA) and its receptor (CD87) in lipodermatosclerosis.
Herouy Y; Aizpurua J; Stetter C; Dichmann S; Idzko M; Hofmann C; Gitsch G; Vanscheidt W; Schöpf E; Norgauer J
J Cutan Pathol; 2001 Jul; 28(6):291-7. PubMed ID: 11401675
[TBL] [Abstract][Full Text] [Related]
17. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Iyer AM; Zurolo E; Boer K; Baayen JC; Giangaspero F; Arcella A; Di Gennaro GC; Esposito V; Spliet WG; van Rijen PC; Troost D; Gorter JA; Aronica E
Neuroscience; 2010 May; 167(3):929-45. PubMed ID: 20219643
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen Activators and Inhibitors in the Corneas of Mice Infected with Pseudomonas aeruginosa.
Berk RS; Katar M; Dong Z; Day DE
Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1561-7. PubMed ID: 11381061
[TBL] [Abstract][Full Text] [Related]
19. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.
Nagai N; De Mol M; Lijnen HR; Carmeliet P; Collen D
Circulation; 1999 May; 99(18):2440-4. PubMed ID: 10318667
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.
Bugge TH; Flick MJ; Danton MJ; Daugherty CC; Romer J; Dano K; Carmeliet P; Collen D; Degen JL
Proc Natl Acad Sci U S A; 1996 Jun; 93(12):5899-904. PubMed ID: 8650190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
